In a groundbreaking advancement for pediatric healthcare, the American Society of Hematology (ASH) in partnership with the International Society on Thrombosis and Haemostasis (ISTH) has unveiled a comprehensive set of clinical practice guidelines dedicated to anticoagulant prophylaxis in non-cardiac pediatric populations vulnerable to venous thromboembolism (VTE). Published in the esteemed journal Blood Advances, these guidelines signify a pivotal stride toward evidence-based pediatric thrombosis care, addressing a historically underserved patient demographic characterized by clinical complexity and heightened risk.
Venous thromboembolism, the pathological formation of thrombi within venous vasculature, has emerged as a substantial cause of morbidity in pediatric patients, notably those with chronic illnesses or requiring hospitalization. Despite its clinical significance, consensus on risk stratification and prophylactic intervention in children has been conspicuously absent, leaving clinicians reliant on extrapolated adult data that inadequately reflect pediatric hemostatic physiology and comorbid dynamics. The ASH-ISTH collaboration fills this critical gap, delivering tailored recommendations grounded in rigorous multidisciplinary evaluation and state-of-the-art research evidence.
The newly released guidelines articulate twelve nuanced clinical recommendations alongside two good practice statements. These directives navigate the intricate balance between prophylaxis efficacy and bleeding risk, guided by patient-specific conditions and underlying pathophysiology. For instance, the panel issues conditional recommendations against routine anticoagulant prophylaxis in pediatric patients presenting with solid tumors, traumatic injuries, or critical illnesses, acknowledging the variable thrombotic risk profiles and potential adverse effects inherent in these groups.
Conversely, particular subpopulations such as children diagnosed with antiphospholipid syndrome or those dependent on long-term total parenteral nutrition may derive prophylactic benefit. Therapeutic decisions in these instances are informed by mechanistic understanding of hypercoagulability states and nutritional influences on hemostatic cascades. Furthermore, the guidelines emphasize the importance of careful counsel and individualized anticoagulant strategies for pediatric patients with acute lymphoblastic leukemia or lymphoma, those equipped with central venous access devices, or those recovering from recent surgical interventions, acknowledging the complex interplay of oncologic, procedural, and device-related thrombosis risks.
A critical feature of the guidelines is their recommendation that healthcare institutions develop standardized protocols to manage interruptions in anticoagulant therapy. This is particularly salient for procedures involving lumbar puncture or spinal anesthesia, where hemostatic manipulations necessitate precision to avoid both thrombotic events and hemorrhagic complications. Such standardized management pathways can optimize patient safety while preserving therapeutic efficacy.
Moreover, the guidelines highlight a significant knowledge gap in the development of pediatric-specific risk assessment models, delineating an urgent need for robust prospective studies. These studies should focus on refining risk stratification tools that incorporate pediatric hemostatic nuances and heterogeneity across different patient subgroups, ultimately facilitating precision medicine approaches in pediatric VTE prophylaxis.
The collaborative effort integrates perspectives from hematologists, thrombosis experts, pediatric clinicians, and individuals with lived experience, ensuring that the guidelines are not only clinically rigorous but also patient-centered. According to Dr. Marisol Betensky, co-chair of the guideline panel and esteemed pediatric hematologist at Johns Hopkins University, these recommendations provide a much-needed evidence-based framework, reducing the reliance on adult VTE data which inadequately represents pediatric pathophysiology and clinical complexity.
The incidence of hospital-acquired VTE in pediatric populations underscores the pressing nature of this initiative. As the second leading preventable cause of harm within pediatric inpatient settings, thrombotic events pose immediate risks and can precipitate long-term complications, such as post-thrombotic syndrome and chronic venous insufficiency. These adverse outcomes impact quality of life and healthcare utilization, amplifying the necessity for proactive, evidence-guided prevention strategies.
The publication of these guidelines represents a collaborative triumph, symbolizing a shared commitment by ASH and ISTH to elevate pediatric thrombosis care worldwide. By offering clear, evidence-based recommendations, these guidelines empower clinicians globally with the tools to identify at-risk pediatric patients and implement judicious anticoagulant prophylaxis tailored to individual risk profiles.
Importantly, ASH and ISTH have maintained an ongoing commitment to pediatric thrombosis, having previously developed revised clinical practice guidelines for the treatment of pediatric VTE. This continuum of expertise and guidance solidifies a framework for comprehensive VTE management in children, spanning from prophylaxis to active treatment.
The guidelines and associated educational materials, including visual summaries and teaching slides, are accessible through hematology.org/VTE, providing a valuable resource for healthcare professionals dedicated to refining pediatric thrombosis care. These tools aim to facilitate knowledge translation and clinical decision-making in diverse care settings.
The American Society of Hematology, founded in 1958, stands at the forefront of hematological research and clinical practice, fostering innovation across the spectrum of blood disorders. Meanwhile, the ISTH, established in 1969, continues to lead international efforts in thrombosis and hemostasis research and education, bolstering evidence-based clinical protocols worldwide. Together, their partnership embodies a unified global endeavor to mitigate the burden of pediatric VTE through rigorous scientific inquiry and expert consensus.
As pediatric thrombosis recognition and management evolve, these guidelines mark an inflection point—a transition from adult-informed extrapolations to dedicated pediatric-focused strategies. This evolution holds promise for improved patient outcomes, highlighting the critical role of collaborative, multidisciplinary efforts in advancing pediatric hematology and thrombosis care.
Subject of Research: Anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE)
Article Title: Comprehensive ASH and ISTH Guidelines Transform Anticoagulant Prophylaxis in Pediatric Venous Thromboembolism
News Publication Date: April 8, 2026
Web References: https://doi.org/10.1182/bloodadvances.2025019415; https://hematology.org/VTE; https://ashpublications.org/bloodadvances/article/9/10/2587/537455/American-Society-of-Hematology-International; https://www.hematology.org/; https://www.isth.org/
Keywords: Pediatric venous thromboembolism, anticoagulant prophylaxis, pediatric hematology, thrombosis prevention, pediatric clinical guidelines, venous thrombosis, antiphospholipid syndrome, total parenteral nutrition, central venous access devices, pediatric oncology, evidence-based medicine, hematology research
Tags: anticoagulant bleeding risk management in childrenASH ISTH pediatric thrombosis carechronic illness and pediatric VTEclinical practice guidelines for pediatric thrombosisevidence-based pediatric anticoagulationhospitalization and pediatric thrombosis riskmultidisciplinary pediatric thrombosis recommendationsnon-cardiac pediatric VTE preventionpediatric anticoagulant prophylaxis guidelinespediatric hemostatic physiology in anticoagulationpediatric thromboembolism risk stratificationvenous thromboembolism risk in children
